Patient
SITE014-0125
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE014 (NLD) (Dr. Moreau)
consented 2026-01-27
Adverse events
5
Serious AEs
2
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 202); relationship: NOT RELATED
Grade 4 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 122); relationship: not assessed; serious criteria: life-threatening
Grade 4 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-10-20 (study day 77); relationship: RELATED; serious criteria: life-threatening
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 75); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 62); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.